A
ANTHEM
vs
B
BSE Sensex 30
Over the past 12 months, ANTHEM has underperformed BSE Sensex 30, delivering a return of -9% compared to the BSE Sensex 30's +6% growth.
Stocks Performance
ANTHEM vs BSE Sensex 30
Performance Gap
ANTHEM vs BSE Sensex 30
Performance By Year
ANTHEM vs BSE Sensex 30
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Anthem Biosciences Ltd
Glance View
Anthem BioSciences Ltd. engages in contract research, development and manufacturing, and organization with fully integrated operations spanning across drug discovery, development and manufacturing. The company is headquartered in Bangalore, Karnataka and currently employs 2,062 full-time employees. The company went IPO on 2025-07-21. The firm helps new and established biotech’s and big pharma, develop, optimize and test proteins, monoclonal antibodies, peptides, large molecules, small molecules, toxins and much more. In addition to product research and development, it helps test drugs for safety, efficacy (in vitro and in vivo), pre-clinical animal studies in a GLP facility, clone development, antibody drug conjugates, research and development and manufacture of highly potent compounds, flow chemistry-based production and large-scale commercial product manufacture. Its product line includes human nutrition, animal health, and industrial products. Under human nutrition, it offers active pharmaceutical ingredients, dietary supplements, probiotics, and enzymes, among others.
